Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 2 of 2 entries
Sorted by: Best Match Show Resources per page
Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma.

Oncology letters

Kinoshita S, Ri M, Kanamori T, Aoki S, Yoshida T, Narita T, Totani H, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S.
PMID: 29928335
Oncol Lett. 2018 Jun;15(6):9450-9456. doi: 10.3892/ol.2018.8501. Epub 2018 Apr 16.

Afuresertib (AFU), a novel inhibitor of the serine/threonine kinase AKT, has clinical efficacy as a monotherapy against hematological malignancies and is expected to be used in combination with standard therapies for multiple myeloma (MM). To develop a more effective...

Cite
Kinoshita S, Ri M, Kanamori T, et al. Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma. Oncol Lett. 2018;15(6):9450-9456doi: 10.3892/ol.2018.8501.
Kinoshita, S., Ri, M., Kanamori, T., Aoki, S., Yoshida, T., Narita, T., Totani, H., Ito, A., Kusumoto, S., Ishida, T., Komatsu, H., & Iida, S. (2018). Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma. Oncology letters, 15(6), 9450-9456. https://doi.org/10.3892/ol.2018.8501
Kinoshita, Shiori, et al. "Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma." Oncology letters vol. 15,6 (2018): 9450-9456. doi: https://doi.org/10.3892/ol.2018.8501
Kinoshita S, Ri M, Kanamori T, Aoki S, Yoshida T, Narita T, Totani H, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S. Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma. Oncol Lett. 2018 Jun;15(6):9450-9456. doi: 10.3892/ol.2018.8501. Epub 2018 Apr 16. PMID: 29928335; PMCID: PMC6004690.
Copy Download .nbib Format: NLM
The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL-1 cell growth.

Clinical and experimental dermatology

Wu JH, Limmer AL, Narayanan D, Doan HQ, Simonette RA, Rady PL, Tyring SK.
PMID: 34115902
Clin Exp Dermatol. 2021 Dec;46(8):1551-1554. doi: 10.1111/ced.14798. Epub 2021 Aug 26.

Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine neoplasm of the skin, which has an exceedingly poor prognosis. The AKT/mammalian target of rapamycin (mTOR) signalling pathway, which plays a pivotal role in the modulation of protein synthesis and...

Cite
Wu JH, Limmer AL, Narayanan D, et al. The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL-1 cell growth. Clin Exp Dermatol. 2021;46(8):1551-1554doi: 10.1111/ced.14798.
Wu, J. H., Limmer, A. L., Narayanan, D., Doan, H. Q., Simonette, R. A., Rady, P. L., & Tyring, S. K. (2021). The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL-1 cell growth. Clinical and experimental dermatology, 46(8), 1551-1554. https://doi.org/10.1111/ced.14798
Wu, J H, et al. "The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL-1 cell growth." Clinical and experimental dermatology vol. 46,8 (2021): 1551-1554. doi: https://doi.org/10.1111/ced.14798
Wu JH, Limmer AL, Narayanan D, Doan HQ, Simonette RA, Rady PL, Tyring SK. The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL-1 cell growth. Clin Exp Dermatol. 2021 Dec;46(8):1551-1554. doi: 10.1111/ced.14798. Epub 2021 Aug 26. PMID: 34115902.
Copy Download .nbib Format: NLM
Showing 1 to 2 of 2 entries